{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:34:15Z","timestamp":1790847255780,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T00:00:00Z","timestamp":1493510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00277-017-2994-x","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T22:39:54Z","timestamp":1493505594000},"page":"1113-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study"],"prefix":"10.1007","volume":"96","author":[{"given":"Alessandro Maria","family":"Vannucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Burn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan","family":"Paranagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Marker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gadbaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,30]]},"reference":[{"issue":"1","key":"2994_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14\u201322. doi:\n10.1038\/sj.leu.2404955","journal-title":"Leukemia"},{"issue":"9","key":"2994_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu. 2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, M\u00fcllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881. doi:\n10.1038\/leu. 2013.163","journal-title":"Leukemia"},{"issue":"9","key":"2994_CR3","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T, MPD Research Consortium (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952\u20131959. doi:\n10.1038\/sj.leu.2404854","journal-title":"Leukemia"},{"issue":"5","key":"2994_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435. doi:\n10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"issue":"7","key":"2994_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol. 2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian J-J (2016) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80 week follow-up from the RESPONSE trial. Haematologica 101(7):821\u2013829. doi:\n10.3324\/haematol. 2016.143644","journal-title":"Haematologica"},{"issue":"5","key":"2994_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1089\/gtmb. 2012.0366","volume":"17","author":"P Collier","year":"2013","unstructured":"Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC (2013) Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers 17(5):429\u2013437. doi:\n10.1089\/gtmb. 2012.0366","journal-title":"Genet Test Mol Biomarkers"},{"issue":"23","key":"2994_CR7","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121(23):4778\u20134781. doi:\n10.1182\/blood-2013-01-478891","journal-title":"Blood"},{"issue":"32","key":"2994_CR8","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO. 2009.23.6075","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418\u20135424. doi:\n10.1200\/JCO. 2009.23.6075","journal-title":"J Clin Oncol"},{"issue":"8","key":"2994_CR9","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072. doi:\n10.1182\/blood-2008-03-143537","journal-title":"Blood"},{"issue":"4","key":"2994_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/leu. 2015.326","volume":"30","author":"JJ Kiladjian","year":"2016","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B (2016) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30(4):776\u2013781. doi:\n10.1038\/leu. 2015.326","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2994-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T03:07:33Z","timestamp":1496372853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2994-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,30]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2994-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,30]]}}}